BiotechTube

Ruxolitinib

Pre-clinicalActive
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Myelofibrosis (PMF)

Conditions

Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness, Polycythemia Vera (PV), Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD), Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

Trial Timeline

— → —

NCT ID
NCT04745637

About Ruxolitinib

Ruxolitinib is a pre-clinical stage product being developed by Novartis for Primary Myelofibrosis (PMF). The current trial status is active. This product is registered under clinical trial identifier NCT04745637. Target conditions include Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF).

What happened to similar drugs?

20 of 20 similar drugs in Primary Myelofibrosis (PMF) were approved

Approved (20) Terminated (6) Active (0)
✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅Duloxetine + PlaceboEli LillyApproved
✅Eszopiclone + PlaceboSumitomo PharmaApproved
✅Eszopiclone + PlaceboSumitomo PharmaApproved
✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved
✅RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
3
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (16)

NCT IDPhaseStatus
NCT05269771Pre-clinicalCompleted
NCT04745637Pre-clinicalActive
NCT04337359Pre-clinicalCompleted
NCT06824103ApprovedRecruiting
NCT06462469ApprovedRecruiting
NCT03491215Phase 1/2Completed
NCT02966353Phase 2Completed
NCT02292446Phase 3Completed
NCT02091752Phase 2Terminated
NCT02049450Phase 2Completed
NCT02072057Phase 2Terminated
NCT02015208Phase 1/2Completed
NCT02087059Phase 3Completed
NCT01877005Phase 2Completed
NCT01317875Phase 1Completed
NCT01392443Phase 2Completed

Competing Products

20 competing products in Primary Myelofibrosis (PMF)

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31